Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | KLK1 | P06870 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.39 |
| ▸ | TACR3 | P29371 | 2/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 7/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.36 |
| ▸ | F9 | P00740 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25155948 | 0.94 | KLKB1 (0.47) | KLKB1KLK1SLC6A9TACR3LOXL2 | |
| SCHEMBL25155149 | 0.90 | KLKB1 (0.39) | KLKB1KLK1LOXL2PDE2AF9 | |
| SCHEMBL31360332 | 0.90 | KLKB1 (0.39) | KLKB1KLK1LOXL2PDE2AF9 | |
| SCHEMBL25155354 | 0.89 | IDO1 (0.39) | KLKB1KLK1SLC6A9LOXL2IDO1 | |
| SCHEMBL31359826 | 0.89 | IDO1 (0.39) | KLKB1KLK1SLC6A9LOXL2IDO1 | |
| SCHEMBL30344712 | 0.85 | LOXL2 (0.37) | KLKB1KLK1LOXL2 | |
| SCHEMBL25155246 | 0.85 | LOXL2 (0.37) | KLKB1KLK1LOXL2 | |
| SCHEMBL25155255 | 0.82 | NPC1 (0.38) | KLKB1KLK1SLC6A9TACR3PDE2A | |
| SCHEMBL25155732 | 0.77 | MTNR1A (0.34) | KLKB1KLK1NPC1RAB9A | |
| SCHEMBL31360248 | 0.77 | MTNR1A (0.34) | KLKB1KLK1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | KLKB1 584/4885KLK1 396/4885SLC6A9 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.